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Structural basis of omalizumab therapy and
omalizumab-mediated IgE exchange
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Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal
structure of the omalizumab–Fab in complex with an IgE-Fc fragment. This structure reveals
the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and
low-afﬁnity IgE receptors, and explains why omalizumab selectively binds free IgE. The
structure of the complex also provides mechanistic insight into a class of disruptive IgE
inhibitors that accelerate the dissociation of the high-afﬁnity IgE receptor from IgE. We use
this structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab
binding. Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with
omalizumab, promotes the exchange of cell-bound full-length IgE with omalizumab-resistant
IgE-Fc fragments on human basophils. This combination treatment also blocks basophil
activation more efﬁciently than either agent alone, providing a novel approach to probe
regulatory mechanisms underlying IgE hypersensitivity with implications for therapeutic
interventions.
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A
llergic diseases represent an over-reaction of the immune
system to normally non-hazardous environmental sub-
stances, such as dust mites, pet dander, pollen or mold,
and the incidence of allergies worldwide is rising1,2. IgE
antibodies are central to most allergic reactions, and bind to
high-afﬁnity receptors (FceRI) present on mast cells and
basophils, sensitizing these cells to respond to allergens. FceRI
is expressed as a trimer with one a-chain and two g-chains or as a
tetramer with an additional b-chain3. The FceRI a-chain
(FceRIa) binds IgE with subnanomolar afﬁnity4,5, and cells
expressing FceRI are preloaded with IgE and primed for
activation. A second IgE receptor (CD23) is expressed on
additional cells, including B lymphocytes, where it is thought to
play a role in IgE-mediated antigen presentation and the feedback
regulation of IgE antibody production6–12.
The IgE-Fc region contains three domains (Ce2–4). All three
domains affect IgE receptor binding, yet the Ce3–4 fragment
independently binds FceRI and CD23 and contains the residues
involved in IgE receptor interactions13–15 (Fig. 1a). The
homodimeric IgE-Fc binds FceRIa asymmetrically, forming two
non-equivalent contacts with FceRIa at the top of each Ce3
domain termed site 1 and site 2 (Fig. 1b) (ref. 5). Conformational
rearrangements between open and closed states within the Ce3–4
fragment, stabilized by FceRIa and CD23 binding, respectively,
allow FceRI and CD23 to function as reciprocal allosteric
inhibitors (Fig. 1b) (refs 14,15). In contrast, Ce2 domains do
not make extensive contact with IgE receptors, but form
intramolecular contacts within IgE, stabilizing a ‘bent,’
asymmetric conformation of the full-length molecule (Fig. 1c).
The primary role of the Ce2 domain is to contribute to the slow
dissociation of IgE from FceRIa (ref. 13).
IgE has been a target for therapeutic development because of its
central role in the allergic response. The anti-IgE monoclonal
antibody omalizumab is currently indicated for the treatment
of moderate to severe persistent asthma and chronic idiopathic
urticaria. Omalizumab has demonstrated robust clinical
efﬁcacy16–18, and has promise for a wide range of other allergic
conditions, including oral food allergen desensitization
regimens19. Omalizumab acts primarily by neutralizing free
serum IgE. Thereby, it also reduces surface levels of IgE on FceRI-
expressing cells, including mast cells and basophils20,21. As IgE
surface levels decline on these allergic effector cells, they lose the
ability to bind allergen and to undergo IgE-dependent activation.
Omalizumab received FDA approval over a decade ago; yet, no
structure of the omalizumab:IgE complex has been determined.
To understand the structural basis of omalizumab:IgE
interactions and its ability to inhibit both FceRI and CD23
binding, we determined the structure of the omalizumab Fab
bound to a disulﬁde bond mutant of the IgE-Fc Ce3-Ce4
fragment (IgE-G335C-Fc3–4) to 2.5 Å (Table 1). Omalizumab
binds to the IgE Ce3 domains outside of the FceRI-binding site,
similar to the anti-IgE Designed Anykyrin Repeat Protein
(DARPin) E2_79, in good agreement with prior mapping studies
of the epitope22–24. The complex structure clariﬁes how
omalizumab blocks IgE interactions with both the high- and
low-afﬁnity receptors. Despite the similarity in omalizumab and
E2_79-binding sites on IgE, E2_79 is a disruptive inhibitor that
can accelerate the dissociation of IgE:FceRI complexes, while
omalizumab has only poor (B1,000-fold weaker) disruptive
activity23,25. Comparison of the omalizumab and E2_79 IgE
complexes provides insights into the mechanism of disruptive
inhibition, which could help in the development of anti-IgE
antibodies with improved disruptive capabilities.
The omalizumab structure also facilitated the design of an
IgE-Fc3–4 mutant (IgE-R419N-Fc3–4) that is resistant to
omalizumab neutralization but is able to bind CD23 and FceRI.
Signiﬁcant experimental evidence has accumulated suggesting
that IgE-dependent homeostatic regulatory pathways respond to
the loss of receptor-bound IgE induced by omalizumab treatment,
and could offset or constrain the therapeutic beneﬁt of the anti-
IgE treatment8,12,26–32. We demonstrate that the IgE-R419N-Fc3–
4 mutant, in combination with omalizumab, can effectively
exchange cell-bound IgE with IgE-R419N-Fc3–4 and that this dual
inhibitor treatment is more potent at blocking basophil activation
than either inhibitor alone. This approach of simultaneously
depleting antigen-speciﬁc IgE, while engaging FceRI and CD23
receptors with an IgE variant, can be used to further probe the
role of IgE-dependent regulatory pathways during anti-IgE
treatment and may provide a route to enhance current anti-IgE
therapies.
Results
Structure of the IgE–omalizumab complex. We previously
described an IgE-Fc3–4 mutant (IgE-G335C-Fc3–4), which con-
tains an engineered disulﬁde bond at position 335 that traps the
IgE-Fc3–4 domain in a closed conformation with reduced
conformational ﬂexibility33 (Fig. 1b). This variant retains high-
afﬁnity binding to omalizumab, but not FceRIa (Supplementary
Figs 1 and 2). Employing this restrained IgE-Fc3–4 variant,
we crystallized the IgE-G335C-Fc3–4:omalizumab–Fab complex
(subsequently referred to as the IgE:omalizumab complex). The
puriﬁed complex (Supplementary Fig. 3a,b) crystalized in the P21
space group, diffracted X-rays to 2.5 Å (Table 1), and the
structure was solved by molecular replacement using the existing
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Figure 1 | Organization and conformational rearrangements of the IgE-Fc. (a) IgE and the relative locations of the FceRIa- (purple) and CD23
(orange)-binding sites. (b) A representation of open and closed conformations of the IgE-Fc3–4 domains (including the IgE–G335C–Fc3–4 mutant locked in a
closed conformation), and a representation of the reciprocal allosteric inhibition by FceRIa (purple) and CD23 (orange). (c) A schematic of the bent
conformation of IgE, and the relative position of the Ce2 domains.
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IgE–G335C–Fc3–4 (ref. 33) and omalizumab–Fab structures34. The
asymmetric unit contains two copies of IgE-G335C-Fc3–4, and four
copies of the omalizumab–Fab, providing four copies of the
IgE:omalizumab interface related by non-crystallographic symmetry
(NCS). Side-chain electron density was well resolved throughout the
IgE:omalizumab interface (Supplementary Fig. 3c).
Analysis of the structure revealed that the omalizumab–Fab
approaches perpendicularly to the IgE Ce3 domain, in contrast to
recently proposed models35, and contacts symmetric binding sites
on the face of the two Ce3 domains of the IgE dimer (Fig. 2a–c).
These contacts are predominantly formed between the
omalizumab–Fab and Ce3 b-sheet residues below the FceRIa-
binding loops (FG, BC and DE; Fig. 2d). Structural alignment of the
IgE:FceRIa complex5 with the IgE:omalizumab complex shows that
the binding loops are only slightly perturbed within the
IgE:omalizumab complex at receptor site 2 (Fig. 2d); thus,
omalizumab does not appear to inhibit IgE:FceRIa interactions by
distorting the FceRIa-binding site. Instead, the omalizumab–Fab is
positioned between the binding sites of both FceRI and CD23,
blocking interactions with both receptors, with the heavy chain
proximal to the CD23 site, and the light chain proximal to the
FceRIa-binding sites (Fig. 2d). Of note, both the position of the
omalizumab epitope on the face of Ce3, and the perpendicular
binding orientation of the omalizumab Fab, suggest that
omalizumab could approach and target a preformed IgE–FceRI
complex.
Impact of IgE-Fc conformation on omalizumab binding. We
previously demonstrated that omalizumab can bind preformed
IgE-Fc3–4:FceRIa complexes, but not full-length IgE:FceRIa
complexes25. Therefore, we hypothesized that the Ce2 domains of
full-length IgE in the IgE:FceRIa complex obscure an
omalizumab-binding site that is exposed in the IgE-Fc3–4:
FceRIa complex. As predicted, alignment of the structures of
IgE:omalizumab and IgE-Fc2-4:FceRIa complexes demonstrates
that the Ce2 domains overlap extensively with an otherwise
exposed omalizumab-binding epitope in the IgE-Fc3–4:FceRIa
structure (Fig. 2e). Therefore, omalizumab’s speciﬁcity for
free IgE is not solely determined by FceRIa competition, but
also by IgE-conformation-dependent masking of its own second
omalizumab epitope. These observations suggest that fragmented
IgE molecules lacking Ce2 could be aggregated by omalizumab,
leading to basophil activation (Supplementary Fig. 4); however,
we have not observed this in human basophils or mast cells25.
Given that the crystal structure lacks the Ce2 domain, it cannot
account for possible contributions of the Ce2 to omalizumab:IgE
interactions. Therefore, we also compared the binding kinetics of
full-length IgE (clone Sus11) to that of the IgE-Fc3–4 fragments.
We hypothesized that the ka of full-length IgE might be slower
than that of IgE-Fc3–4 because the Ce2 domains obscure one of
the two symmetric omalizumab epitopes (Fig. 1), and, as
expected, the ka of full-length IgE was 15–30-fold lower as
compared with the IgE-Fc3–4 fragments tested (Supplementary
Fig. 1). Surprisingly, the kd of the full-length IgE was also
4.5–10.9-fold slower than any of the three IgE-Fc3–4 fragments
tested (Supplementary Fig. 1). This results in only minor
differences in the overall equilibrium Kd (B3.5-fold) between
intact IgE and the IgE-Fc3–4 fragments.
The IgE Ce3 domains also show signiﬁcant conformational
ﬂexibility, adopting closed and open states relative to the Ce4
domains that are associated with CD23 and FceRI binding,
respectively. The potential impact of these conformational
changes on omalizumab binding has not been fully assessed.
The localization of the omalizumab epitope on the face of the Ce3
domain suggested that omalizumab would interact equally well
with both open and closed forms of the IgE-Fc. To examine this
possibility, we compared the binding kinetics of omalizumab with
wild-type IgE-Fc3–4, the IgE-G335C-Fc3–4 mutant (locked in the
closed conformational state33) and with IgE-Fc3–4 bound to
FceRIa (stabilized in the open state by receptor binding).
IgE-G335C-Fc3–4 exhibited similar kinetics in omalizumab-
binding studies as wild-type IgE-Fc3–4 (Supplementary Fig. 1)
but was unable to bind FceRIa (Supplementary Fig. 2). These data
suggest that omalizumab can bind closed conformations of IgE
efﬁciently, and indicate that the crystal structure reﬂects the
normal binding mode of omalizumab for IgE-Fc3–4.
No mutations have been identiﬁed that stabilize the open
IgE-Fc3–4 conformational state, making studies of the omalizu-
mab interaction with this state more challenging. However,
omalizumab binds to IgE-Fc3–4:FceRIa complexes25, and our
structural analysis demonstrates that one of the two Ce3 domain
epitopes is fully accessible to omalizumab. Therefore, to examine
the potential impact of the open Ce3 domain conformation on
omalizumab binding, we measured the kinetics of omalizumab
binding to preformed IgE-Fc3–4:FceRIa complexes. This analysis
revealed an association rate constant (ka) for omalizumab
with IgE-Fc3–4 bound to FceRIa complexes that was closer to
full-length IgE alone and slower than unbound IgE-Fc3–4.
The similarity in association rates between full-length IgE and
IgE-Fc3–4:FceRIa complexes may be in part because of the fact
that each binding partner contains a single exposed Ce3 domain
(Supplementary Fig. 5). The dissociation rate constant (kd) for the
omalizumab:IgE-Fc3–4:FceRIa complexes was also similar to
that of the measured rates for IgE:FceRIa or omalizumab:IgE
complexes (Supplementary Figs 1 and 2), consistent with the
dissociation of either of these two interfaces during measurement.
Together, these kinetic data demonstrate that the IgE-Fc Ce3
conformations have little or no impact on omalizumab binding
Table 1 | Data collection and reﬁnement statistics.
IgE-G335C-Fc3–4:omalizumab–Fab
Data collection
Space group P 1 21 1
Cell dimensions
a,b,c (Å) 100.10, 107.14, 151.04
a,b,g () 90.00, 95.18, 90.00
Resolution (Å) 37.61–2.50 (2.59–2.50)
Rmerge 0.115 (2.009)
CC1/2 0.999 (0.756)
CC* 1.000 (0.928)
I/sI 22.09 (1.94)
Wilson B-factor 61.89
Completeness (%) 97.80 (95.73)
Redundancy 26.9 (23.0)
Reﬁnement
Resolution (Å) 2.50
No. of reﬂections (work/test) 107,541/1,512
Rwork/Rfree 22.07/23.9
No. of atoms
Macromolecule 20,083
Ligand/ion 484
Water 59
B-factors
Macromolecule 70.40
Ligand/ion 98.20
Water 61.10
r.m.s.d.
bond lengths 0.003
bond angles 0.812
r.m.s., root mean square; r.m.s.d., root mean square deviation.
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and that, in free IgE, the Ce2 domain may alter the kinetics of
omalizumab binding with a small effect on the afﬁnity of the
interaction. These data support the structural observation that
omalizumab:IgE interactions are primarily mediated by a stable
epitope contained in the Ce3 domain. These kinetic data also
highlight the critical role of the Ce2 domains in the intact
receptor-bound IgE, which are required to mask an omalizumab
epitope that is not directly blocked by the FceRI itself.
The omalizumab epitope. To establish which residues fall within
the omalizumab epitope on IgE, we analysed the interfaces of the
omalizumab:IgE complex with PISA36. All NCS copies shared the
majority of contacts, which extend along the length of the Ce3
domain, involve 23 IgE residues and bury B725Å2 of surface
area on IgE (Fig. 3a). Previously identiﬁed IgE mutants that
inhibit omalizumab binding, studied in an intact IgE heavy chain,
correspond well with the binding interface observed in the crystal
structure (Fig. 3b) (ref. 24). After correcting for different
numbering schemes and IgE sequences from prior studies
(Supplementary Fig. 6), all residues implicated in omalizumab:
IgE binding are within the predicted omalizumab:IgE interface,
and many participate in hydrogen bonds (R376, S378, K380,
Q417) or salt bridges (R419) predicted by the crystal structure
(Fig. 3c–e). Notably, IgE E414, a residue implicated in
omalizumab-binding studies with the mutants E414R/Q,
appears to form an intrachain salt bridge with IgE R376
(Fig. 3d) and may be essential for stabilizing the conformation
of the adjacent omalizumab-binding residues (Fig. 3d,e).
The omalizumab complementarity-determining region (CDR)
loops, with the exception of the light chain CDR3 loop,
contact IgE. CDR residues previously shown to be required for
omalizumab binding either contact IgE (light chain D32 in CDR1
(Fig. 3c) and heavy chain H101 in CDR3 (Fig. 3e)) or form
interactions with neighbouring CDR loops (heavy chain CDR3
H105 and H107) (ref. 24). The complex contains ﬁve hydrogen
bonds distributed throughout the omalizumab:IgE interface and
two salt bridges between light chain residues D32 and D34 and
IgE R419 (Fig. 3c–e). The heavy chain CDR3, which shows the
most extensive conformational change from the unbound
omalizumab:Fab structure (PDB ID: 4X7S), also contains three
aromatic side chains that contact IgE (Y102, H101, F103; Fig. 3e).
Outside of the omalizumab heavy chain CDR3, four additional
aromatic side chains contact IgE: Y33 in the heavy chain CDR1,
Y36 in the light chain CDR1 and Y53 and Y57 in the light chain
CDR1. Therefore, it appears that a network of hydrogen bonds,
salt bridges and extensive hydrophobic interactions facilitate
omalizumab:IgE interactions.
The IgE residues interacting with omalizumab CDRs are
largely distinct from those that engage FceRIa (ref. 24). IgE
residues P426 and R427 are the only minor overlapping portions
of the omalizumab:IgE-Fc3–4 and FceRIa:IgE-Fc3–4 interfaces as
calculated with the PISA analysis (Fig. 3a). Each residue is unique
to site 2 of the FceRIa:IgE complex. The residues are adjacent to
the omalizumab light chain framework region (Fig. 3a and
Supplementary Fig. 7) and are peripheral to the omalizumab:IgE
interface. Only one NCS-related IgE chain has well-resolved
electron density for R427, while the remaining copies do not
(Supplementary Fig. 7). Within this chain neither R427 nor P426
make contacts (o4Å) directly with omalizumab; however, R427
indirectly interacts with the light chain framework through a
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Figure 2 | The IgE:omalizumab complex. An overview of the IgE:omalizumab complex. Blue, omalizumab heavy chain; orange, omalizumab light chain;
and tan, IgE-G335C-Fc. (a) A cartoon diagram of the biological unit, showing IgE-G335C-Fc3–4 and two omalizumab Fabs binding symmetric sites.
(b) The side view of the biologic unit of the IgE:omalizumab complex shows the omalizumab–Fab approaching perpendicularly relative to the Ce3–Ce4
domains. (c) The top view of the complex reveals the two nonoverlapping and symmetric omalizumab epitopes on each Ce3 domain within the IgE.
(d) Comparison of IgE:omalizumab, FceRIa (1F6A) and CD23 (4EZM) complexes demonstrates that omalizumab binds between CD23 and FceRIa-binding
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sulfate ion (Supplementary Fig. 7). Mutations at R427 (R427E)
lead to a minor reduction in omalizumab binding (25–56%),
suggesting that this residue can affect omalizumab:IgE inter-
actions24. In contrast, the R427E mutation substantially reduced
FceRIa binding to IgE, while another mutant series that
contained a R427A mutation only partially reduced FceRIa
binding37. Although omalizumab may directly compete with
FceRIa for IgE residues, the extent of direct competition and
binding site overlap involves at most two amino acids.
The structural basis of FceRI and CD23 competition.
Omalizumab inhibition of FceRIa and CD23 binding could arise
from contributions of multiple structural mechanisms, including
direct competition for receptor-binding residues on IgE, steric
clashes caused by physical overlap of omalizumab and IgE
receptors and potential omalizumab-induced conformational
changes in IgE. The kinetic and structural data suggest that
omalizumab does not induce conformational changes in FceRIa-
binding loops or in the relative positions of the Ce3 domains that
could affect receptor binding. Omalizumab also shows minimal
overlap with FceRIa-binding residues; however, physical overlap
between the bound omalizumab Fab and FceRIa could be
substantial and critical to omalizumab activity.
To gain quantitative insight into the contribution of inhibitor
overlap in blocking IgE interactions with FceRIa and CD23,
we calculated the theoretical volumes of atomic overlap between
omalizumab and its two IgE receptors. First, we performed a
structural alignment of the Ce3 domain of the IgE:omalizumab
complex with the Ce3 domain of the IgE:FceRIa complex at
sites 1 and 2 (Fig. 4a). This alignment strategy accounts for the
variability of open and closed IgE conformations observed across
IgE crystal structures14,33,38. We then calculated the volume of
atomic overlap between the superimposed omalizumab and
FceRIa proteins. This analysis revealed that, for the omalizumab-
binding site proximal to FceRIa binding site 2, there are
signiﬁcant steric clashes between the antibody light chain and
both domains of the FceRIa receptor (Fig. 4a), while no clashes
exist at site 1. These structural data indicate that omalizumab’s
mechanism of FceRIa inhibition involves substantial steric
conﬂict with the receptor at site 2, while direct competition for
FceRIa-binding residues is limited.
Omalizumab has also been shown to inhibit the binding
of CD23 (ref. 39). Both substantial steric overlap between
omalizumab and CD23, and direct competition for IgE-binding
residues by the omalizumab heavy chain, contribute to
omalizumab inhibition of CD23 binding (Fig. 4b,c). The degree
of steric overlap of omalizumab with CD23 is signiﬁcantly greater
than that observed for FceRIa (Fig. 4b). Binding-site comparisons
also demonstrate a more extensive overlap between IgE residues
that engage omalizumab and CD23 in their respective complexes
as compared with FceRIa (Fig. 4c).
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11610 ARTICLE
NATURE COMMUNICATIONS | 7:11610 | DOI: 10.1038/ncomms11610 | www.nature.com/naturecommunications 5
Steric overlap and inhibitor-induced FceRIa complex dissociation.
We recently described a class of IgE inhibitors derived from
Designed Ankyrin Repeat Protein (DARPin) libraries, capable
of disrupting IgE:FceRI complexes23,25. These agents target
preformed IgE:FceRIa complexes found on mast cells and
basophils and accelerate the dissociation rate constant to release
free IgE. The activated release of IgE on the surface of effector
cells might prove beneﬁcial in treating acute allergic reactions and
enhance the clearance of allergen-speciﬁc IgE during anti-IgE
therapy by targeting both cellular and serum pools of IgE
simultaneously. We have demonstrated that a bivalent DARPin
(bi53_79) containing a non-competitive IgE-binding domain and
a disruptive competitor domain dissociates complexes with
greater efﬁciency in vitro and shows greater potency than
omalizumab in blocking passive cutaneous anaphylaxis in mice
bearing the human FceRI receptor25. To our surprise, we also
observed that omalizumab is not strictly a competitive inhibitor
of IgE:FceRIa interactions, but at higher concentrations it is also
capable of targeting and disrupting IgE:FceRIa complexes25.
We have published the crystal structure of the DARPin-based
inhibitor E2_79 (ref. 23), which is able to accelerate the
dissociation of FceRIa complexes at concentrations B3,000
above the E2_79:IgE KD (ref. 23). In contrast, omalizumab
shows an ability to disrupt preformed FceRIa complexes at
concentrations that are much higher (B1,000,000-fold greater)
than the omalizumab:IgE KD (ref. 25), indicating that it is much
less efﬁcient at the process of binding to and dissociating these
preformed complexes. We hypothesized that this difference in
disruptive capability was related to the binding-site locations for
E2_79 and omalizumab on IgE and the level of atomic overlap
between each inhibitor and receptor. We therefore compared
the structure of both the E2_79:IgE-G335C-Fc3–4 complex
(E2_79:IgE) and the omalizumab:IgE complex.
The structure of the E2_79:IgE complex demonstrated that
the E2_79-binding sites do not overlap with FceRIa-binding
residues, while omalizumab exhibits only minor peripheral
interactions with two FceRIa-binding residues23. Instead,
similar to omalizumab, E2_79 exhibited steric conﬂicts with
FceRIa in aligned structures of the complexes. Given that both
agents can disrupt preformed IgE:FceRIa complexes25, we sought
to quantitatively compare their relevant steric clashes with FceRIa
when bound to IgE, by computing the predicted volume of
atom–atom overlap of each inhibitor with FceRIa in aligned
complex structures. This analysis reveals that omalizumab has
roughly three times the volume of atomic overlap with FceRIa
compared with E2_79 (omalizumab and FceRIa¼ 1,183Å3
versus E2_79 and FceRIa¼ 401Å3). The omalizumab steric
conﬂicts extend along the length of the omalizumab light chain
and FceRIa N-terminal domain, while the E2_79 steric conﬂicts
are more localized near the IgE:FceRIa interface (Fig. 4a and 4d)
(ref. 40). Since the E2_79 and omalizumab-binding sites are
substantially overlapping on the IgE-Fc (Supplementary Fig. 8),
this large difference in steric overlap with FceRIa stands out as a
prominent structural feature that correlates with the relative
disruptive activities of these inhibitors. Conformational dynamics
in the IgE:FceRIa complex may transiently allow E2_79 associ-
ation and subsequent acceleration of FceRIa dissociation23. Given
the signiﬁcantly larger region of steric conﬂicts observed between
omalizumab and FceRIa, conformational states of the IgE:FceRIa
that could accommodate omalizumab association may simply be
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less accessible and/or occur with lower frequency, explaining its
lower activity. A signiﬁcant fraction of the steric clashes with both
inhibitors occur between the protein backbone of omalizumab
or E2_79 and carbohydrate groups on FceRIa (Fig. 4e).
These carbohydrate groups likely explore a wider range of
conformations, and may help facilitate the association of these
inhibitors to preformed IgE:FceRIa complexes.
A single IgE mutation prevents omalizumab binding. To
further validate observations from the crystal structure, we
produced an additional IgE-Fc3–4 mutant. IgE residue R419 lies at
the interface of the IgE:omalizumab complex, forming contacts
with both light and heavy chain CDR loops (Fig. 3c) and
participating in salt bridges. Mutation of R419 to an asparagine
(R419N) introduces the glycosylation consensus sequence—
asparagine valine threonine (NVT) (Fig. 5a). We hypothesized
that by mutating this residue we would abolish omalizumab
binding by introducing a glycosylation site at the core of the
omalizumab epitope.
The R419N mutation induced a shift in the mass of
recombinant IgE-Fc3–4 as assessed by SDS–PAGE and gel
ﬁltration, consistent with the introduction of an additional
N-linked glycan (Fig. 5a,b). The IgE-Fc3–4 contains two N-linked
glycosylation sites, N371 and N394 (refs 41,42). We have found in
recombinant preparations of IgE-Fc3–4 that glycosylation at N371
is heterogeneous and leads to a minor band in puriﬁed material
(Fig. 5b). Both major and minor species of IgE-R419N-Fc3–4
remain in similar proportions to wild-type IgE-Fc3–4 species, with
similar mobility shifts in SDS–PAGE. Furthermore, the shift in
apparent mass for IgE-R419N-Fc3–4 relative to wild-type IgE-Fc3–
4 was lost on digestion with PNGaseF, conﬁrming that it is caused
by N-linked glycosylation (Fig. 5b). This additional glycosylation
in the middle of the omalizumab epitope completely abolishes
omalizumab binding, but only slightly perturbs IgE-R419N-Fc3–4
binding to FceRIa as assessed by surface plasmon resonance
(SPR; Fig. 5c,d and summary data Supplementary Figs 1 and 2).
Taken together, these data demonstrate that the R419N mutation
introduces a novel glycosylation site to yield an omalizumab-
resistant IgE-Fc3–4 variant.
Exchange of IgE on human basophils. The paradigm of using
anti-IgE treatment to deplete free IgE (both allergic and non-
allergic species) has proven successful for controlling allergic
diseases. During omalizumab therapy, omalizumab neutralizes
free serum IgE and slowly decreases surface levels of IgE on
allergic effector cells. Therefore, it is impossible to simultaneously
replace depleted allergen-reactive species with benign IgE species
because of the requirement for continued excess omalizumab to
be present during treatment. Since IgE-dependent homeostatic
regulatory pathways could potentially counteract anti-IgE
therapies, we sought to explore the possibility of replacing rather
than removing patient IgE. We hypothesized that omalizumab-
resistant IgE variants or fragments could be used in combination
with omalizumab to effectively exchange the native IgE on human
cells bearing FceRI or CD23.
Over the course of omalizumab treatment, free IgE levels and
IgE surface levels on basophils decline relatively rapidly within
days43, while mast cell IgE levels persist for signiﬁcantly longer44.
The rapid decline of basophil-associated IgE may in part be
driven kinetically by basophil turnover in vivo45. However, within
the experimental timeframe for our ex vivo experiments with
human whole blood (24–48 h), we did not observe signiﬁcant
loss of cell surface IgE at doses corresponding to the
mean omalizumab serum concentrations from clinical trials46.
Therefore, we employed supraphysiologic doses of omalizumab
(25 mM) to enhance the removal of IgE as described previously25.
These doses were used here to accelerate the loss of cell-bound
IgE to facilitate these exchange experiments. Nonetheless, lower
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therapeutic doses of omalizumab are sufﬁcient to capture free IgE
and reduce cell surface levels of IgE over time, which is the basis
of omalizumab’s therapeutic effect.
To track the addition, removal and exchange of IgE species,
we employed biotinylated IgE-Fc3–4 or omalizumab-resistant
IgE-R419N-Fc3–4, and the JW8 human/mouse chimeric IgE
(composed of a human IgE heavy chain and a mouse-l-light
chain). The JW8 mouse-l-light chain allowed us to track IgE
reloading on stripped basophils in parallel with the biotinylated
IgE-Fc3–4 proteins. We ensured that all antibody reagents used in
staining carried the mouse-k-light chain, or were rat antibodies,
to avoid nonspeciﬁc binding from the anti-mouse-l-light-chain
antibody used to track JW8-IgE.
We isolated blood from three donors, and depleted surface IgE
on basophils by treating each sample with the disruptive inhibitor
E2_79 (Fig. 6a, gating scheme Supplementary Fig. 9). We then
reloaded the cells with JW8-IgE (Fig. 6a), while also verifying that
stripped cells could be reloaded with biotinylated IgE-Fc3–4 or
IgE-R419N-Fc3–4 species (Fig. 6a). Therefore, we could remove
native IgE species, reload cells with homogeneous traceable IgE
and subsequently track the removal or exchange of JW8-IgE
(Fig. 6b,c). The l-light-chain-speciﬁc staining of JW8 and biotin-
speciﬁc staining of the IgE-Fc3–4 variants distinguished human
basophils that had no JW8-IgE or biotinylated-IgE-Fc3–4, a mix of
both species, or a single IgE species (Fig. 6b,c).
Overnight omalizumab treatment of cells that had been
homogenously reloaded with JW8-IgE completely removed the
JW8-IgE from the cell surface, as shown by an overlay of the
pre- and post-treatment ﬂow cytometry proﬁles (arrow, Fig. 6d).
Co-administration of IgE-Fc3–4 and omalizumab also showed
complete depletion of JW8-IgE species but no exchange for
IgE-Fc3–4 at 1 mgml 1 IgE doses (Fig. 6d). In contrast, co-
administration of omalizumab-resistant IgE-R419N-Fc3–4 with
omalizumab depleted JW8-IgE surface levels, and facilitated
IgE-R419N-Fc3–4 reloading to levels observed in IgE-stripped
basophils treated with IgE-R419N-Fc3–4 alone (Fig. 6d).
Therefore, co-administration of omalizumab and IgE-R419N-
Fc3–4 effectively exchanges the receptor-bound IgE on human
basophils for IgE-R419N-Fc3–4 ex vivo. Even when wild-type
IgE-Fc3–4 doses far beyond physiologic IgE levels were employed
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(10 mgml 1), only minimal reloading of wild-type IgE-Fc3–4 was
observed, in contrast to the dramatic reloading of IgE-R419N-Fc3–4
(Supplementary Fig. 10). This effect was not restricted to FceRI-
expressing basophils. CD23þ B-cells treated with omalizumab
and IgE-Fc3–4 variants retained surface IgE-R419N-Fc3–4, but
were stripped of wild-type IgE-Fc3–4 (Supplementary Fig. 11b).
Furthermore, both wild-type IgE-Fc3–4 and IgE-R419N-Fc3–4
occupancy of the CD23 receptor stabilized surface CD23
and increased CD23 surface levels (Supplementary Fig. 11c).
Importantly, IgE-mediated stabilization of surface CD23 prevents
the release of soluble CD23 (sCD23), a soluble mediator shown to
upregulate IgE expression8,32.
IgE-R419N-Fc3–4 and omalizumab act synergistically. To
determine whether IgE-R419N-Fc3–4 could enhance the effect
of omalizumab treatment in human cells, we performed basophil-
activation tests. Basophils were isolated from healthy donors,
treated with DARPins to remove surface IgE (using the enhanced
bi53_79 DARPin25) and reloaded with the 4-hydroxy-
3-nitrophenylacetyl (NP)-speciﬁc JW8-IgE. The resultant
NP-reactive basophils were then left untreated or were treated
with omalizumab (at therapeutic concentrations of 500 nM),
IgE-R419N-Fc3–4 or combinations of both agents for 3 (Fig. 7a)
or 6 days (Fig. 7b) before NP-antigen challenge. Given that
IgE:FceRIa complexes dissociate slowly, and omalizumab is a
weak disruptive inhibitor at the therapeutically relevant
concentration used, we did not anticipate a rapid response in
basophils homogenously reloaded with JW8-IgE. Accordingly,
after 3 days, there were no signiﬁcant reductions in basophil
responses as compared with untreated controls (Fig. 7a). Of note,
omalizumab transiently increased basophil sensitivity on day 3,
although this effect was overcome by day 6, presumably as
omalizumab neutralized a greater fraction of JW8-IgE previously
bound to cells. Although this effect was not signiﬁcant, it does ﬁt
with clinical studies, which suggest that basophil sensitivity is
increased on a per IgE basis during omalizumab therapy30. There
was signiﬁcantly less activation in cells treated with a
combination of omalizumab and IgE-R419N-Fc3–4 (100 nM) as
compared with omalizumab alone by day 3 (Fig. 7a), suggesting
that combination therapy could offset this transient effect in
omalizumab-treated samples. By day 6, a signiﬁcant reduction in
basophil activation was observed in all treatment arms as
compared with the untreated controls (Fig. 7b). This result was
surprising, given that IgE-R419N-Fc3–4 alone was able to inhibit
basophil reactivity at 1 nM concentrations (Fig. 7b). Furthermore,
in combination with omalizumab, 1 nM IgE-R419N-Fc3–4 almost
completely inhibited basophil activation (Fig. 7b). The additive
effect of omalizumab (500 nM) and IgE-R419N-Fc3–4 (1 nM)
should be minor if each agent acted only as a competitive
inhibitor for JW8-IgE:FceRIa interactions, suggesting that these
agents can act synergistically to block basophil activation.
Discussion
Anti-IgE therapy remains an important tool for the management
of allergic disorders, and novel second-generation anti-IgE
therapies will soon join omalizumab. Yet, the aetiology of allergic
disorders is complex and optimal therapeutic responses will likely
come from treatment regimens that target and modulate multiple
immunological processes.
Here we have clariﬁed the structural basis for omalizumab-
mediated inhibition of IgE binding to both FceRI and CD23. This
analysis revealed similarities between the disruptive inhibitor
E2_79 and omalizumab, and provides a mechanistic framework
to develop antibody-based therapies that can accelerate the
dissociation of IgE:FceRIa complexes. Such agents could rapidly
disarm basophils and mast cells, allowing them to achieve a
therapeutic effect faster.
We have also demonstrated that mutant IgE fragments, in
conjunction with omalizumab treatment, can exchange native
IgE on human cells for IgE fragments, maintaining the occupancy
of both high- and low-afﬁnity IgE receptors. We pursued
this approach, given the experimental evidence that basophils
increase in sensitivity on a per IgE basis during omalizumab
treatment28–30, and that IgE production can be regulated
by IgE:CD23 signalling8,11,12,31,32. These observations raise
signiﬁcant questions about the impact of therapeutic IgE
depletion, and suggest that homeostatic responses to the loss of
IgE could offset or constrain the therapeutic beneﬁt of anti-IgE
treatment. Our experimental observations provide a system to test
some of these regulatory pathways and could potentially be used
as an adjunct therapy with omalizumab. To this end, we have also
demonstrated that IgE-R419N-Fc3–4 can act synergistically
with omalizumab ex vivo at very low doses to inhibit basophil
activation. This ﬁnding suggests that simultaneously targeting
FceRI and IgE with competitive inhibitors could enhance
therapeutic responses. Prior studies have demonstrated that
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non-activating ligands can antagonize FceRI responses to
activating ligands by sequestering receptor-proximal signalling
components47, and it is possible that IgE-R419N-Fc3–4:FceRI
complexes could suppress activation through such mechanisms,
in addition to competing for receptor occupancy. Sustained FceRI
receptor occupancy could also suppress homeostatic responses to
the loss of IgE on omalizumab-treated basophils.
Finally, the dissociation of allergen-speciﬁc IgE on mast cells
located in peripheral tissues is slow, and the effectiveness of
anti-IgE within these compartments is poorly understood44. Given
that the FceRI on mast cells has been shown to drive IgE tissue
localization48, co-administration of omalizumab and omalizumab-
resistant IgE fragments that bind FceRI may enhance the exchange
of allergen-speciﬁc IgE in peripheral sites, and contribute to the
therapeutic beneﬁt of anti-IgE treatment.
Despite the potential utility of IgE exchange, and promising
ex vivo results, the concept is far from clinical application.
Unexpected antibody responses to the R419N IgE, although
unlikely, could prevent the development of any universally benign
IgE variant for exchange therapy, and could induce anaphylactic
antibody responses to receptor-bound IgE fragments. Yet, our
approach with IgE-R419N-Fc3–4 does have two distinct advan-
tages in this regard. First, N-linked glycosylation events are
effective at masking antibody epitopes, and could reduce the
immunogenicity of IgE-R419N-Fc3–4 (ref. 49). Second, the new
antigenic surface generated by truncating IgE to the Ce3-4
domains would be largely inaccessible once bound to FceRIa,
preventing any antibody responses to this epitope from
crosslinking receptor-bound IgE fragments. Given that anti-IgE
and anti-FceRIa antibody responses are relatively common, and
are not always pathological50, it is possible that such an approach
could be well tolerated.
Methods
Preparation of omalizumab and recombinant proteins. Fab fragments of
Omalizumab (Novartis) were prepared by digestion over an immobilized ﬁcin
agarose resin (Pierce) in 10-mM citrate buffer with 25mM cysteine and 5mM
EDTA at pH 6.0 for 5 h. The Fab fragments were puriﬁed in two steps with protein
G (Pierce) and gel ﬁltration to yield homogenous omalizumab–Fab. Protein G
columns were washed with phosphate buffer over a pH gradient (8.0, 7.0, 6.0 and
5.0) and Fab was eluted with glycine buffer at pH 2.5. Insect-cell-derived IgE-Fc3–4,
IgE-G335C-Fc3–4 and FceRIa were expressed in High Five insect cells and puriﬁed
using Ni-NTA afﬁnity chromatography and further puriﬁed using gel ﬁltration on
a Superdex 200 10/300 GL column (GE). All insect vectors have been previously
published: IgE-Fc3–4 (ref. 33), IgE-G335C-Fc3–4 (ref. 33) and FceRIa51.
Mammalian-derived IgE-Fc3–4 and the R419N mutant, used in all cell-based assays,
were cloned into the pYD7 vector (National Research Council (NRC), Canada)
with a vascular endothelial growth factor (VEGF) signal sequence from the
pTTVH8G vector (NRC). Constructs were transfected using 25-kDa linear
polyethylenimine (Polysciences), and transiently expressed in suspension HEK-6E
cells (NRC) for 120 h according to the supplier’s protocols. Cell supernatants were
ﬁltered through 0.45-mM Durapore ﬁlter (Millipore) and incubated with Ni-NTA
resin (Qiagen) for 1 h at room temperature, washed with 10 resin bed volumes of
wash buffer (25mM imidazole in PBS at pH 7.4) and eluted with 2 resin bed
volumes of elution buffer (300mM imidazole in PBS at pH 7.4). The eluted protein
was then concentrated using an Amicon Ultra-15 ﬁlter unit (Millipore) and further
puriﬁed with gel ﬁltration on a Superdex 200 10/300 GL column (GE). Protein used
for experiments with human basophils was subsequently buffer-exchanged into
sterile PBS pH 7.4 using an Amicon Ultra-15 ﬁlter unit (Millipore). The DARPins
E2_79 and bi53_79 were cloned into the pQE-30 expression vector between BamHI
and HindIII restriction sites, and expressed in XL-1 blue E. coli (NEB) at 37 degrees
overnight following induction with isopropyl-b-D-thiogalactoside. Soluble
DARPins were puriﬁed using Ni-NTA afﬁnity chromatography, followed by gel
ﬁltration on a Superdex 200 10/300 GL column (GE).
Crystallization conditions. Crystals were grown in hanging drops in 0.2M
Lithium Sulfate, 0.1M Tris pH 8.5 and 41% PEG 400. A volume of 0.1 ml of
complex at 9mgml 1 was added to 0.1 ml of well solution. Crystals were harvested
and frozen in the same crystallization buffer for data collection.
Structure determination of the IgE:omalizumab complex. Diffraction data were
collected in two 360 sweeps of one crystal on the microfocus beamline 12-2 at the
Stanford Synchrotron Radiation Lightsource, and data were indexed, integrated
and scaled using the HKL2000 suite52. The omalizumab-C335 crystals grew in
the P21 space group with the unit cell dimensions a¼ 100.10 Å, b¼ 107.14 Å,
c¼ 151.04 Å and b¼ 95.18. A molecular replacement solution was obtained using
Phaser-MR in the Phenix package (version 1.9)53 using the models 4GT7 (for
C335-IgE-Fc)33 and 4X7S (for omalizumab–Fab)34. Automated model building to
improve early models was performed using Phenix AutoBuild, and reﬁnement
was performed using rounds of Phenix Reﬁne and manual model building with
Coot (version 0.8.1) (ref. 54). NCS restraints were identiﬁed automatically in
phenix.reﬁne by sequence similarity and default root mean squared deviation
tolerance of o2Å. NCS restraints were applied in early rounds of reﬁnement and
removed in ﬁnal rounds of reﬁnement. The ﬁnal model was reﬁned to 2.5 Å
(Table 1) and was validated using MolProbity and Phenix comprehensive
validation. The model had Ramachandran-favoured conformations in 497% of
residues and 0.2% of residues were outliers. The relatively high B-factors after
reﬁnement are expected, given the high-average Wilson B-factor (61.89).
Calculation volume overlaps. Structural alignments with omalizumab:IgE and
E2_79:IgE complexes were made with the Ce3 domain at site 2 of the FceRIa
complex. The alignment with the CD23:IgE complex was made with either Ce3
domain within the CD23 complex (similar results were found with both alignments
in this symmetric complex). The coordinates of each IgE-binding molecule
(FceRIa, omalizumab, E2_79 and CD23) from these aligned complexes were then
loaded into pdbset (CCP4) and centred within an arbitrarily deﬁned unit cell to
accommodate the full chain. The coordinates of the aligned and transformed
structures were then input into sfall (CCP4) to generate an atom map from the
polypeptide chain (solvent atoms and ligands were not included), and input into
mapmsk (CCP4) to make a map mask. The resulting map masks were input into
overlapmap (CCP4) using the MAP INCLUDE function, keeping only density of
overlapping regions of each inhibitor with the receptor complex in question. The
volume of the resulting overlap maps were then calculated with the volumes tool in
Chimera40.
Biotinylation of proteins. IgE-Fc3–4 or R419N-IgE-Fc3–4 was biotinylated
using EZ-Link Sulfo-NHS-LC-biotin (Pierce), with a 30-fold molar excess of
sulfo-NHS-LC-biotin for 30min at room temperature. The reaction was stopped
using 1.0M Tris pH 7.4, and proteins were dialysed overnight into PBS pH 7.4,
and sterile-ﬁltered with 0.22-mm ﬁlter.
Basophil IgE exchange experiments. Blood was drawn from two healthy
volunteers and a third volunteer with a history of food allergy ranging in age from
21 to 37 (the protocol for this study was approved by the Institutional Review
Board of Stanford University, and all informed consent was obtained from all
subjects). Blood was collected in heparin vacutainer tubes (BD), and washed in
10 blood volumes of BF buffer (RPMI-1640 (Life Technologies) supplemented with
10% fetal calf serum (FCS; Gibco) and 1% penicillin/streptomycin (Gibco)).
Washed blood cells were then suspended in their original blood volume in BF
buffer and treated with or without E2_79 at 25 mM for 2 h at 37 C to remove
surface IgE. Stripped cells were then reloaded with IgE-JW8 at 120–300 ngml 1 as
estimated from supplier’s supplied concentration range (AbD Serotec) or were left
untreated. These cells were then treated overnight at 37, as speciﬁed in the ﬁgure
legends with omalizumab, IgE-Fc variants or vehicle controls. The following day
cells were washed three times with BF buffer at 4 C and stained for analysis.
Flow cytometry for basophil IgE exchange. After washing, treated cells and
controls were incubated with human Fc-block (BD), and stained with the following
antibodies as described in ﬁgure legends (at 1:100 dilution unless stated): IgE-FITC
(eBiosciences clone: IgE21), FceRIa-APC (eBiosciences clone AER-37 at 1:50
dilution), anti-biotin AF-488 (eBiosciences clone: BK-1/39), anti-mouse-lambda-
light-chain PE (BioLegend clone: RML-42), CD123 PE-Cy5 (BD clone: 9F5 at 1:20
dilution), HLA-DR PE-Cy7 (BioLegend clone L243 at 1:80 dilution), CD203c
BV421 (BioLegend clone: NP4D6 at 1:50 dilution), CD19-PE (BD clone: HIB19 at
1:50), CD23-BV421 (BioLegend EBVCS-5 at 1:50 dilution) and Aqua Live Dead
stain (Life Technologies). Stained cells were then lysed with RBS lysis buffer
(BioLegend) for 5min at room temperature, and washed with FACS buffer (PBS
pH 7.4 supplemented with 10% FCS). Data were collected on a DxP FACSCAN
from Cytek Development in Fremont, CA (10 colours with three lasers—488, 639,
407) using FlowJo CE and analysed using FlowJo (version 10).
SPR assays. SPR measurements were conducted on a BIAcore X100 device and
evaluated with the BIAevaluation software (GE Healthcare, Fairﬁeld, USA). For
kinetic analysis of different IgE fragments on omalizumab and FceRIa, 1,000
response units of omalizumab or rhFceRIa were immobilized in acetate buffer
(pH 4.5 for omalizumab and pH 4.0 for rhFceRIa) on ﬂow cell 2 of a CM5 chip
(GE Healthcare). Flow cell 1 was activated and deactivated without immobilization,
according to the manufacturer’s protocol. The different IgE fragments (produced as
described above) or full-length Sus11 IgE were diluted in HBS-EPþ running
buffer (GE Healthcare) and injected for 120 s at a constant ﬂow rate of
10 ml min 1. Dissociation was assessed for 240 s under constant buffer ﬂow.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11610
10 NATURE COMMUNICATIONS | 7:11610 | DOI: 10.1038/ncomms11610 | www.nature.com/naturecommunications
For each measurement, the chip surface was regenerated with 50mM NaOH.
Individual sensorgram curves were exported to Excel, and graphs were prepared
with the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, USA). In all
experiments, unspeciﬁc binding to ﬂow cell 1 was subtracted from the signal on
ﬂow cell 2.
Functional assay with primary human basophils. Human primary basophils
were isolated from whole blood of volunteers with approval from the local ethics
committee (KEK Bern). Informed consent was obtained from all donors in
accordance with the Helsinki Declaration. Human basophils were isolated from
three different donors, with total IgE levels ranging from 35 to 78 kU l 1 by using
Percoll density centrifugation of dextran-sedimented supernatants with further
puriﬁcation with the Miltenyi basophil isolation kit II (Miltenyi Biotec, Bergisch
Gladbach, Germany), as previously described55. Total IgE levels of the donors were
determined using ImmunoCAP (Phadia, Uppsala, Sweden). Puriﬁed primary
human basophils were seeded at 0.5 105 cells per well in a 96-well plate in 50ml of
RPMI containing 10% heat-inactivated FCS, 100 IUml 1 penicillin and
100mgml 1 streptomycin (medium). Cells were kept in a cell incubator at 37 C,
5% CO2. For desensitization, cells were treated with 50 mM disruptive anti-IgE
inhibitor bi53_79 for 8 h in the presence of 10 ngml 1 rhIL-3 and subsequently
washed three times with 150ml PBS to remove dissociated IgE and anti-IgE
inhibitor from the supernatant. For resensitization, cells were incubated with
100 nM JW8-IgE (NBS-C BioScience, Vienna, Austria) for 2 h in the presence of
10 ngml 1 rhIL-3. Subsequently, cells were washed two times with 150 ml PBS and
treated with omalizumab, IgE-R419N-Fc3–4 or a combination of these molecules
for 3 or 6 days at the indicated concentrations. For determination of basophil
activation, cells were stimulated with 1–1,000 ngml 1 NIP(7)BSA (BioSearch
Technologies, Petaluma, USA) in the presence of 10 ngml 1 rhIL-3 for 30min
at 37 C, 5% CO2. Subsequently, cells were stained with 10 ml anti-CD63 FITC
anti-CCR3-PE staining mix (FK-CCR Flow CAST Bu¨hlmann Laboratories AG,
Scho¨nenbuch, Switzerland) for 20min at room temperature. At least 3 103
basophils were acquired on a FACSCalibur device. Data were analysed with the
FlowJo V10 software (TreeStar, Ashland, OR).
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